PIK3CA and neoplasm: There was a significant decrease in the variant allele frequency (VAF) of mutant PIK3CA in Patient X from pre to post-trial, suggesting possibly that copanlisib may have inhibited the tumour clone bearing the PIK3CA mutation and also highlighting potential heterogeneity of response between the tumors from patient X and Y (Figure 2).